Related Experiment Video
Updated: May 17, 2026

High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds
Published on: January 23, 2018
The sodium-glucose cotransporter 2 inhibitor empagliflozin reverses hyperglycemia-triggered vascular endothelial cell
Qian Cheng1, Rui Du2, Jing Liu1
1Department of Anesthesia, Huzhou Maternity & Child Health Care Hospital, Huzhou, China.
Introduction:
Hyperglycemia-induced endothelial injury is a major contributor to diabetic vasculopathy. While sodium-glucose transporter2 (SGLT2) in renal proximal tubules plays a critical role in diabetes, its expression and function in kidney endothelial cells, particularly regarding sex-specific disease progression, remain unclear.
Material And Methods:
SGLT2 expression in kidney endothelial cells was examined in male streptozotocin (STZ)-induced diabetic miceusing immunostaining. In human umbilical vein endothelial cells (HUVECs) treated with high glucose, we investigated the impact ofSGLT2 on mitochondrial dynamics following empagliflozin treatment. Molecular mechanisms were elucidated using qRT-PCR and Westernblot. Therapeutic efficacy was evaluated by histological analysis.
Results:
SGLT2 was significantly upregulated in kidney endothelial cells of diabetic male mice. High glucose increased SGLT2 expressionin HUVECs, promoting mitochondrial fission and reducing fusion. Both SGLT2 siRNA knockdown and empagliflozin treatment markedlyenhanced mitochondrial fusion. Mechanistically, empagliflozin activated AMPK, increasing KLF4 expression and promoting mitochondrialfusion, thereby protecting against endothelial dysfunction. AMPK inhibition abrogated empagliflozin's protective effects in diabetic mice.
Conclusions:
SGLT2 critically regulates endothelial dysfunction under hyperglycemic conditions through the AMPK/KLF4-mitochondrialdynamics axis. Empagliflozin protects both proximal tubules and kidney endothelial cells in diabetes. Given accelerated diabetic kidneydisease progression in males, our male mouse model findings provide clinically relevant insights into sex-specific therapeutic responsesto SGLT2 inhibitors in diabetic vasculopathy.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors
Type II Diabetes II: Pathophysiology
Secondary Active Transport
Secondary Active Transport